ASND vs. EW: A Head-to-Head Stock Comparison
UpdatedHere’s a clear look at ASND and EW, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.
Company Overview
EW stands out with 44.64 billion USD in market value—about 4.68× ASND’s market cap of 9.55 billion USD.
EW carries a higher beta at 1.13, indicating it’s more sensitive to market moves, while ASND remains steadier at 0.40.
ASND trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while EW remains a standard domestic listing.
| Symbol | ASND | EW |
|---|---|---|
| Company Name | Ascendis Pharma A/S | Edwards Lifesciences Corporation |
| Country | DK | US |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Medical - Devices |
| CEO | Mr. Jan Moller Mikkelsen | Mr. Bernard J. Zovighian |
| Price | 158.1 USD | 76.1 USD |
| Market Cap | 9.55 billion USD | 44.64 billion USD |
| Beta | 0.40 | 1.13 |
| Exchange | NASDAQ | NYSE |
| IPO Date | January 28, 2015 | March 27, 2000 |
| ADR | Yes | No |
Performance Comparison
This chart compares the performance of ASND and EW over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).
Hover over the lines to see the investment’s value and total return (%) at specific dates.
Data is adjusted for dividends and splits.
Valuation Metrics Comparison
The section examines key financial ratios to assess the valuation of ASND and EW based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.
- ASND posts a negative P/E of -24.55, reflecting last year’s net loss, while EW at 10.68 signals healthy earnings.
- ASND posts a negative forward PEG of -2.23, hinting at anticipated earnings decline, whereas EW at 0.86 has projections for stable or growing earnings.
- ASND has a negative P/B ratio of -44.19, indicating its liabilities exceed assets (negative equity). EW, with a P/B of 4.47, maintains positive shareholder equity.
- ASND has a negative Price-to-Free Cash Flow ratio of -27.43, signaling it consumed more cash than it produced over the last year—an important liquidity warning. In contrast, EW (P/FCF 153.99) indicates positive free cash flow generation.
| Symbol | ASND | EW |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | -24.55 | 10.68 |
| Forward PEG Ratio (TTM) | -2.23 | 0.86 |
| Price-to-Sales Ratio (P/S, TTM) | 22.88 | 8.06 |
| Price-to-Book Ratio (P/B, TTM) | -44.19 | 4.47 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | -27.43 | 153.99 |
| EV-to-EBITDA (TTM) | -35.74 | 23.87 |
| EV-to-Sales (TTM) | 23.78 | 7.64 |
| EV-to-Free Cash Flow (TTM) | -28.50 | 145.90 |
Dividend Comparison
Neither ASND nor EW currently pays a dividend yield; this often indicates they are reinvesting earnings for growth, prioritizing long-term expansion over immediate cash returns to shareholders.
| Symbol | ASND | EW |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
Financial Strength Metrics Comparison
This section dives into the financial resilience of ASND and EW, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.
- ASND’s quick ratio of 0.71 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas EW at 3.45 maintains a comfortable buffer of liquid assets.
- ASND has negative equity (debt-to-equity ratio -4.46), an unusual warning sign, while EW at 0.07 maintains a conventional debt-to-equity balance.
- ASND has negative EBIT (interest coverage -3.72), unable to cover interest, while EW shows “--” (negligible interest expense).
| Symbol | ASND | EW |
|---|---|---|
| Current Ratio (TTM) | 1.04 | 4.18 |
| Quick Ratio (TTM) | 0.71 | 3.45 |
| Debt-to-Equity Ratio (TTM) | -4.46 | 0.07 |
| Debt-to-Assets Ratio (TTM) | 0.80 | 0.05 |
| Interest Coverage Ratio (TTM) | -3.72 | -- |